Abstract
Introduction The COVID-19 pandemic underlined that guidelines and recommendations must be made more accessible and more understandable to the general public, including adults, parents, and youth, to improve health outcomes. The objective of this study is to the public’s (youth, parents, and adult populations) understanding, usability, satisfaction, intention to implement, and preference for different ways of presenting COVID-19 health recommendations derived from the COVID-19 Living Map of Recommendations and Gateway to Contextualization (herein referred to as the RecMap).
Methods and Analysis This is a protocol for a mixed-methods study. We will conduct a pragmatic allocation-concealed, blinded superiority randomized controlled trial (RCT) in three populations: adults (21 years of age or older), parents (18 years or above and are a parent or legal guardian of a child under 18 years old), and youth (15 to 24 years old), with at least 240 participants in each population. The trial will consist of an online survey and optional one on one interview. Prior to initiating the RCT, all PLRs were refined with relevant stakeholder input. In each population group, the intervention arm will receive a PLR format while the control arm will receive the original recommendation format as originally published by the guideline organizations (herein referred to as Standard Language Version). Our primary outcome is understanding, and our secondary outcomes are accessibility and usability, satisfaction, intended behavior, and preference for the two recommendation formats. Each population’s results will be analyzed separately. We will pool the results across populations using meta-analysis, and also explore potential interaction and subgroup effects within each population. At the end of each survey, participants will be invited to participate in a one-on-one semi-structured interview to explore reasons for their choices and learn for future research. All interviews will be analyzed using thematic analysis. Interpretation will be iterative as data coding proceeds.
Ethics and Dissemination Through Clinical Trials Ontario (CTO), the Hamilton Integrated Research Ethics Board has reviewed and approved this protocol (Project ID: 3856). The University of Alberta will also be submitting for ethics approval. All potential participants will be required to provide informed consent. The findings from this study will be disseminated through open-access publications in peer-reviewed journals.
Strengths and limitations of this study
We are following a mixed methods approach: randomized controlled trial and qualitative interviews. The qualitative results will supplement and help explain our quantitative findings.
This protocol is reported in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT), which enhances transparency and completeness. The trial uses previously validated outcomes from similar trials. This will strengthen the credibility of our results.
Our study is testing an evaluated PLR format, which makes our intervention stronger, and is recruiting internationally, which ensures the inclusion of a diverse population.
Recruitment will take place online using social media, and data will be collected using an online survey. This allows for self-selection and limits accessibility to those who have no or limited digital access, which in turn limits generalizability.
While the recommendations are offered in multiple languages through the RecMap, the study is only testing English Plain Language Recommendations.
Competing Interest Statement
NJB receives research funding from Canadian Institutes of Health Research, CHILD-BRIGHT, and the Cundill Centre for Child and Youth Depression. NJB also declares consulting fees from Nobias Therapeutics, Inc. All other authors (RC, LS, MM, SS, LH, MO, SE, DPR, JLM, EAA, TK, AM, AB, MP, JR, SDS, JS, MF, MK, TL, AS, KP, and HJS) have declared no competing interest.
Clinical Trial
NCT05358990
Clinical Protocols
Funding Statement
This work is supported by the ′Canadian Institutes of Health Research′ (CIHR), grant number: GA3-177732. McMaster University is the sponsor of the trial and can be contacted through the principal investigator, Dr. Holger Schünemann at schuneh@mcmaster.ca.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Hamilton Integrated Research Ethics Board (HiREB) of McMaster University gave ethical approved for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymous survey data will be publicly available from an open access online repository to be chosen within 2 years of data collection.